[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@AponiaAnalytics aponia_analytics

Several biotech companies have recently made significant announcements. TG Therapeutics reported a strong Q3 revenue of $161.7m, driven by Briumvi sales, and raised its 2025 guidance. Regeneron also posted a XX% increase in Q3 revenue to $3.68b, driven by Dupixent and Eylea HD. Additionally, Pfizer reported solid Q3 results, with a revenue of $16.7b and raised its 2025 EPS guidance.

Engagements: XXXXX #

X Week XXXXXX +6.20%
X Month XXXXXXX -XX%
X Months XXXXXXXXX +489%
X Year XXXXXXXXX +9,074%

Mentions: XXX #

X Week XXX -XXXX%
X Month XXXXX -XX%
X Months XXXXXX +267%
X Year XXXXXX +4,836%

Followers: XXXXX #

X Week XXXXX -XXXX%
X Month XXXXX -XXXX%
X Months XXXXX +4.80%
X Year XXXXX +198%

CreatorRank: XXXXXXX #

Social Influence

Social category influence stocks XXXXX% finance XXXXX% cryptocurrencies XXXX% countries XXXX% technology brands XXXX% currencies XXXX% social networks XXXX% exchanges XXXX%

Social topic influence $lly #72, $nvo #156, $xbi #44, $sgmo #22, strong 2.31%, $onc #5, ai 2.02%, $idya #3, $janx #23, $ptgx #15

Top accounts mentioned or mentioned by @vertexpharmas @usfda @lineagecell @cariboubios @avidresearch @citi @uniqurenvs @beamtx @seedy19tron @wavelifesci @jonathanwosen @siixandserello @maximizebelief2 @alex_jones_2028

Top Social Posts

Top posts by engagements in the last XX hours

"$AGIO #FDA 🦉 FDA lets the mitapivat PDUFA date slip leaving Agios in a holding pattern as labeling and REMS talks continue. And no new data was sought but no timeline was offered"
X Link 2025-12-08T20:03Z 5113 followers, XXX engagements

"$ABVX $AUPH"
X Link 2025-12-11T18:21Z 5113 followers, XXX engagements

"$MDGL 🦉Madrigal reported 2-year Phase X data showing Rezdiffra improved liver stiffness fibrosis and portal hypertension markers in MASH cirrhosis. Gains held after treatment breaks. Data shared at AASLD 2025. #newsrelease"
X Link 2025-11-10T15:28Z 5112 followers, XXX engagements

"$MDGL 🦉 CFO Mardi Dier exercised 4173 options at $XXXXXX and sold multiple blocks between $570$596 leaving 10440 shares. One 10b5-1 plan governed the trades. #form_4"
X Link 2025-12-04T21:40Z 5112 followers, XXX engagements

"$NTRA 🦉 Natera snaps up Foresight to bring its ultra-sensitive MRD tech in-house. The $275M stock deal also adds proven lymphoma tools and together the teams broaden Nateras tumor testing reach"
X Link 2025-12-05T17:52Z 5112 followers, XX engagements

"$XBI $MRK $CDTX"
X Link 2025-12-06T18:04Z 5113 followers, XXX engagements

"$CDTX $ABVX $SNY"
X Link 2025-12-07T14:40Z 5113 followers, XXX engagements

"$ARVN 🦉 Arvinas reported preclinical data showing ARV-393 plus glofitamab drove up to XX% tumor-growth inhibition and full regressions in lymphoma models. A Phase X combo cohort starts in 2026. #form_8K"
X Link 2025-12-08T19:57Z 5113 followers, XXX engagements

"$EOSE 🦉 Director Russell Stidolph sold about 765k EOSE shares near $XX and exercised 296439 low-priced options. He now owns 2.12M shares indirectly via AltEnergy plus 364355 directly. #form_4"
X Link 2025-12-09T13:58Z 5112 followers, XXX engagements

"$ABBV $AZN $LLY #China"
X Link 2025-12-11T18:11Z 5113 followers, XXX engagements

"$MDGL $INSM $RYTM"
X Link 2025-12-04T17:14Z 5113 followers, XXX engagements

"$VKTX $MDGL $LLY"
X Link 2025-12-04T20:59Z 5113 followers, XXX engagements

"$CDTX $ABVX $NKTR"
X Link 2025-12-06T18:23Z 5113 followers, XXX engagements

"$VRTX 🦉 Vertex shares big news as CASGEVY shows strong results in children as young as five. And the company now prepares global filings for 1H26 while adult data remain solid"
X Link 2025-12-06T18:37Z 5113 followers, XXX engagements

"$SNDX $VRTX $CRSP"
X Link 2025-12-07T14:23Z 5113 followers, XXX engagements

"$VRTX 🦉 Vertex chair Jeffrey Leiden sold 63781 shares for $28.7M cutting his stake by 72.6%. EVP Charles Wagner sold 14000 shares for $6.38M as total insider sales hit 151073 shares over XX days"
X Link 2025-12-09T16:17Z 5113 followers, XX engagements

"$CIFR $VELO $BACQ $RDW $WULF"
X Link 2025-12-11T18:05Z 5113 followers, XXX engagements

"$NVDA $NBIS $CRWV $IREN"
X Link 2025-12-11T18:34Z 5113 followers, XXX engagements

"$CRWV $NBIS $IREN $CIFR $WULF #AI"
X Link 2025-12-11T18:36Z 5113 followers, XXX engagements

"$SRPT 🦉 Sarepta CFO Ryan Wong reports two small disposals as XXX shares are withheld for tax on RSU vesting at $XXXXX. His direct stake stands at 136045 shares after the adjustments. #form_4"
X Link 2025-12-11T18:55Z 5113 followers, XXX engagements

"$GMAB 🦉 Genmab schedules its 2025 R&D and ASH data review for today at XX a.m. ET with the session streamed live and archived online. The event runs independently of the ASH meeting. #events"
X Link 2025-12-11T19:00Z 5113 followers, XX engagements

"$ONC 🦉 BeOne Medicines to present at Guggenheim Healthcare Innovation Conference on Nov XX and Jefferies Global Healthcare Conference on Nov XX 2025. #pressrelease"
X Link 2025-10-28T16:28Z 5119 followers, XXX engagements

"$ONC 🦉BeOne Medicines Q325 Takeaways Blowout quarter: revenue $1.41B (+41% YoY) on BRUKINSA $1.0B (+51%); TEVIMBRA $191M (+17%). Gross margin XXXX% (300 bps) on richer BRUKINSA mix/productivity. Operating leverage visible: GAAP OpInc $163M vs $120M YoY; GAAP EPS/ADS $1.09; non-GAAP EPS/ADS $XXXX. Free cash flow $354M; cash to $4.11B (helped by financing and Royalty Pharma deal; note new $885M royalty liability). Opex grew 1116% but SG&A fell to XX% of sales (vs 46%)"
X Link 2025-11-06T16:22Z 5119 followers, XXX engagements

"$MRUS $HALO 🦉 Merus licensed Halozymes ENHANZE to develop a subcutaneous version of petosemtamab adding upfront and milestone payments. Halozyme will receive low-mid single-digit royalties if the therapy reaches market"
X Link 2025-11-17T20:25Z 5120 followers, XXX engagements

"$MRUS $HALO 🦉 Merus licensed Halozymes ENHANZE to create a subcutaneous version of petosemtamab adding upfront and potential milestone payments. Halozyme may earn low-mid single-digit royalties on future sales"
X Link 2025-11-17T20:52Z 5121 followers, XXX engagements

"$ALKS $AVDL"
X Link 2025-11-19T15:51Z 5115 followers, XXX engagements

"$SGMO 🦉Sangamo is quietly building a neurology franchise: six partnered programs tied to Genentech Astellas Lilly Alexion and Takeda sit alongside two wholly owned candidates giving the company a mix of early-stage breadth and big-pharma validation that investors increasingly watch"
X Link 2025-11-21T15:03Z 5119 followers, XXX engagements

"$NTLA $ALNY $BBIO"
X Link 2025-11-23T21:44Z 5123 followers, XXX engagements

"$RHHBY $LCTX"
X Link 2025-11-27T16:01Z 5120 followers, XXX engagements

"$MRUS 🦉 Merus VP Harry Shuman exercised 8300 options into common shares on Nov. XX. He then sold 8300 shares at $XXXXX leaving 11002 shares directly held. #form_4"
X Link 2025-11-30T18:25Z 5121 followers, XX engagements

"$IONS 🦉 Director Joseph Wender filed to sell 14479 shares worth about $1.19M on Dec. X through Goldman Sachs under a 10b5-1 plan. Recent sales totaled roughly 84600 shares in three months. #form_144"
X Link 2025-12-02T18:19Z 5116 followers, XXX engagements

"$IONS 🦉 Ionis director Joseph Wender filed to sell 33.6k shares valued at $2.50M following prior October sales under a 10b5-1 plan. The amendment updates Table I details from the earlier filing. #form_144"
X Link 2025-12-02T18:25Z 5116 followers, XXX engagements

"$AXSM 🦉 Officer Herriot Tabuteau filed to sell 49252 shares ($7.0M) via Goldman Sachs on Dec. X under a 10b5-1 plan. Recent 3-month sales exceed 270k shares. #form_144"
X Link 2025-12-03T11:44Z 5123 followers, XX engagements

"$JANX 🦉 Officer Byron C. Robinson plans to sell 63125 shares ($1.03M) via Morgan Stanley after option exercise on Dec. 2; no sales in prior X months. #form_144"
X Link 2025-12-03T11:48Z 5119 followers, XXX engagements

"$AXSM 🦉 Axsome CEO Herriot Tabuteau filed to sell 49252 shares valued at $7.0M through Goldman Sachs. The filing follows multiple sales since September under a 10b5-1 plan. #form_144"
X Link 2025-12-03T11:56Z 5123 followers, XXX engagements

"$JANX #Janux_Therapeutics"
X Link 2025-12-03T12:19Z 5115 followers, XXX engagements

"$JANX #Janux_Therapeutics"
X Link 2025-12-03T12:20Z 5115 followers, XXX engagements

"$ABBV $VKTX"
X Link 2025-12-04T17:19Z 5115 followers, XXX engagements

"$RPRX $DNLI"
X Link 2025-12-04T17:33Z 5115 followers, XXX engagements

"$DNLI $RPRX"
X Link 2025-12-04T17:39Z 5115 followers, XXX engagements

"$IONS 🦉 Joseph Wenders trust sold 28000+ shares at $80.66$81.23 leaving 36035 indirect shares and 16000 direct shares. Sales were under a 10b5-1 plan. #form_4"
X Link 2025-12-04T21:42Z 5115 followers, XXX engagements

"$nktr $abvx $kymr"
X Link 2025-12-05T17:44Z 5123 followers, 1007 engagements

"$VKTX $PTGX $IDYA"
X Link 2025-12-05T17:53Z 5123 followers, XXX engagements

"$BPMC $SNY $COGT"
X Link 2025-12-05T17:58Z 5123 followers, XXX engagements

"$SOFI $RDDT $VEEV $PSTG"
X Link 2025-12-05T17:58Z 5115 followers, XXX engagements

"$ALMS $XBI $IBB"
X Link 2025-12-05T18:00Z 5117 followers, XXX engagements

"$AXSM 🦉 Axsomes CEO exercised expiring options at $XXXX and sold 79973 shares at $144148 leaving 7229 direct shares. The filing also shows 7.34M shares held indirectly. #form_4"
X Link 2025-12-05T18:09Z 5119 followers, XXX engagements

"$ACLX 🦉 T. Rowe Price reported 9.6M Arcellx shares with 9.3M sole voting power representing XXXX% of the float. The firm filed as an investment adviser under Rule 13d-1(b). #form_13G/A"
X Link 2025-12-05T18:21Z 5120 followers, XXX engagements

"$FLNC $EOSE"
X Link 2025-12-06T18:23Z 5123 followers, XXX engagements

"$OCUL $RVPH $PRAX"
X Link 2025-12-06T18:27Z 5123 followers, XXX engagements

"$BEAM 🦉 Beam shares new risto-cel data showing strong lasting boosts in fetal hemoglobin for XX sickle-cell patients. And after treatment patients recover quickly and avoid severe crises"
X Link 2025-12-06T18:39Z 5120 followers, XXX engagements

"$ARVN 🦉 Arvinas shows that combining ARV-393 with glofitamab drives much stronger tumor shrinkage in preclinical lymphoma models. And the company plans to test this chemo-free combo in a Phase X study next year"
X Link 2025-12-06T18:40Z 5121 followers, XXX engagements

"$PTGX #Rusfertide"
X Link 2025-12-07T14:23Z 5121 followers, XXX engagements

"#FDQA $SGMO"
X Link 2025-12-07T14:24Z 5124 followers, XXX engagements

"$SGMO #Prion"
X Link 2025-12-07T14:25Z 5125 followers, XXX engagements

"$PFE #ASH25 $SGMO"
X Link 2025-12-07T14:43Z 5123 followers, XXX engagements

"$PTGX #ASH25"
X Link 2025-12-07T14:46Z 5120 followers, XXX engagements

"$ACLX #myeloma 🦉 Arcellx posted XX% ORR and XX% CR/sCR in its Phase X myeloma trial while 12-month PFS hit 82%. And since no delayed neurotoxicity surfaced the company reaffirmed its 2026 launch plan"
X Link 2025-12-07T14:52Z 5115 followers, XXX engagements

"$NVO $LLY $XBI"
X Link 2025-12-08T16:30Z 5120 followers, XXX engagements

"$IBRX #Anktiva $NWBO #DCVax"
X Link 2025-12-08T16:31Z 5116 followers, 1440 engagements

"$XBI $IBB $GPCR"
X Link 2025-12-08T16:38Z 5117 followers, XXX engagements

"#China $LLY #Mounjaro"
X Link 2025-12-08T16:39Z 5119 followers, XXX engagements

"$SRPT 🦉 Sarepta granted CEO Douglas Ingram $12M in new equity awards split between time-based RSUs and performance-linked units tied to Incentive EBITDA. Awards vest over up to three years. #form_8K"
X Link 2025-12-08T20:17Z 5116 followers, XXX engagements

"$RHHBY 🦉 Roche posts three-year STARGLO data showing Columvi-GemOx doubling survival versus R-GemOx in R/R DLBCL. And approvals now span 50+ countries as safety stays steady"
X Link 2025-12-08T20:19Z 5121 followers, XX engagements

"$LLY 🦉 Lilly brings back Nobel chemist Carolyn Bertozzi to its board adding her to Science & Technology and Ethics committees as the company leans deeper into oncology and immunology"
X Link 2025-12-08T20:31Z 5117 followers, XX engagements

"$OVID 🦉 Janus Henderson reported a XXXX% stake in Ovid holding 7.11M shares with shared voting and disposal power. Additional Series A/B warrants remain unexercised due to the cap. #form_13G"
X Link 2025-12-08T20:46Z 5118 followers, XXX engagements

"$XENE $SGMO"
X Link 2025-12-09T12:40Z 5115 followers, XXX engagements

"$NWBO $IBRX #Anktiva"
X Link 2025-12-09T12:42Z 5115 followers, XXX engagements

"$GPCR $LLY $NVO $WVE"
X Link 2025-12-09T12:45Z 5125 followers, XXX engagements

"$PRME $BEAM"
X Link 2025-12-09T12:53Z 5115 followers, XXX engagements

"$HALO 🦉 Halozyme pulls in Jim Lang the deal-maker who scaled EVERSANA and stitched two dozen acquisitions before its tie-up with Waltz Health. Now he takes a board seat steering strategy from day one"
X Link 2025-12-09T13:09Z 5116 followers, XX engagements

"$ACLX 🦉 Arcellx reported iMMagine-1 Phase X data showing XX% ORR and XX% CR/sCR with no delayed neurotoxicity. The company reiterated plans for a 2026 launch. #form_8K"
X Link 2025-12-09T13:14Z 5115 followers, XXX engagements

"$JNJ 🦉 Johnson & Johnson locks in a January slot at J.P. Morgans healthcare summit with leaders set for an 11:15 a.m. fireside chat and a webcast replay rolling out after the event"
X Link 2025-12-09T13:16Z 5119 followers, XX engagements

"$GMAB 🦉 Genmab unveils ASH data showing epcoritamab driving strong responses in Richter transformation with two-year monotherapy results and early combo signals pointing to meaningful activity in this aggressive setting"
X Link 2025-12-09T13:23Z 5115 followers, 1159 engagements

"$JANX 🦉 A Janux officer filed to sell 50000 shares after exercising options valued at $826K; he also sold 63125 shares earlier this month for $1.03M. #form_144"
X Link 2025-12-09T13:39Z 5116 followers, XXX engagements

"$NVS 🦉 Novartis said a quarter of metastatic breast #cancer patients taking Kisqali went four years without their disease progressing. New NATALEE data also showed the drug cut the risk of cancer returning in early-stage cases"
X Link 2025-12-09T14:11Z 5119 followers, XX engagements

"$PFE #GLP1 🦉 Pfizer struck a $2.1B deal for rights to YaoPharmas Phase X GLP-1 pill YP05002 starting with a $150M upfront. The company will take over global development and test combos with its GIPR antagonist"
X Link 2025-12-09T16:27Z 5117 followers, XX engagements

"$NVO #LLY $PFE $AMGN $MTSR 🦉Drugmakers are pivoting from injectable #GLP1 therapies to new oral GLP-1 pills that are cheaper to produce and easier for patients to use a shift that could significantly broaden access to weight-loss medications"
X Link 2025-12-09T16:59Z 5116 followers, XXX engagements

"$TERN $GPCR $KYMR $WVE"
X Link 2025-12-10T15:32Z 5119 followers, XXX engagements

"$IDYA #IDEAYA #Breast_Cancer"
X Link 2025-12-10T15:58Z 5115 followers, XXX engagements

"$MRVI $XBI $IBB"
X Link 2025-12-10T16:16Z 5115 followers, XXX engagements

"$NBIS $NVDA $MSFT #AI"
X Link 2025-12-10T16:16Z 5116 followers, XXX engagements

"$TERN 🦉 Terns prices a $650M upsized equity deal at $XX a share pushing 16.25M shares into the market as demand spikes. The banks get a 30-day option for 2.44M more with closing set for Dec. 11"
X Link 2025-12-10T19:23Z 5115 followers, XX engagements

"$ACLX 🦉 Arcellx held its FDA pre-BLA meeting for anito-cel reaffirming a 2026 launch plan. Updated Phase X iMMagine-1 multiple myeloma data to be presented at ASH 2025. #newsrelease #myeloma"
X Link 2025-11-03T18:28Z 5113 followers, XXX engagements

"$IONS 🦉At AHA 2025 $IONS unveiled Phase X CORE/CORE2 data showing olezarsen cut triglycerides by up to XX% and reduced acute pancreatitis events by XX% the first therapy ever to do so in sHTG. #newsrelease"
X Link 2025-11-08T18:14Z 5115 followers, XXX engagements

"$IONS 🦉American Heart Association (AHA) Scientific Sessions #events OLEZARSEN IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA Primary Results of CORE-TIMI 72a & CORE2-TIMI 72b"
X Link 2025-11-08T18:29Z 5115 followers, XXX engagements

"$IONS 🦉Ionis reported Phase X CORE and CORE2 trials of olezarsen cut triglycerides by up to XX% and reduced acute pancreatitis events by XX% in severe hypertriglyceridemia. FDA filing expected by year-end with 2026 PDUFA target. #form8K #FDA"
X Link 2025-11-10T14:31Z 5115 followers, XXX engagements

"$EOSE $NRG #AI"
X Link 2025-11-30T17:55Z 5114 followers, XXX engagements

"$GMAB 🦉 Genmab closed $2.5B in notes. It combined XXXX% 2032 secured and XXXX% 2033 unsecured debt with new loan facilities. The funds will support its Merus acquisition"
X Link 2025-12-04T21:06Z 5114 followers, XXX engagements

"$GILD $ACLX 🦉 Anito-cel steals the spotlight with a XX% ORR and XX% CR in tough myeloma cases and safety stays steady. Since PFS and OS keep rising Kite and Arcellx now point to a potential 2026 launch"
X Link 2025-12-07T15:09Z 5114 followers, XXX engagements

"$GMAB 🦉 Genmab reports EPKINLY + R2 cut progression risk by XX% and hit a XX% ORR in R/R FL. Since CR reached XX% and results hit The Lancet the combo now stands as a newly approved second-line option"
X Link 2025-12-07T15:12Z 5116 followers, XXX engagements

"$AXSM 🦉 CEO Herriot Tabuteau exercised expiring options and sold 79973 shares at $145148. His direct stake fell to 7229 shares while 7.34M remain held indirectly. #form_4"
X Link 2025-12-07T15:35Z 5113 followers, XXX engagements

"$PTGX #ASH25"
X Link 2025-12-09T13:35Z 5115 followers, XXX engagements

"$HALO 🦉 Halozyme appointed James Lang to its board with a term through 2027 and standard non-employee director pay. No related-party ties disclosed. #form_8K"
X Link 2025-12-09T13:42Z 5114 followers, XX engagements

"$NVO $AKRO 🦉 Novo Nordisk closed its $4.7B purchase of Akero at $XX per share. The deal adds a $X CVR tied to U.S. approval of EFX and removes Akero from Nasdaq"
X Link 2025-12-09T14:02Z 5114 followers, XXX engagements

"$NVO #GLP1 #SunPharma #India 🦉 Novo Nordisk moved to block Sun Pharma from making semaglutide after DRL won room to export its version. The judge sent the case to another bench. Patent expiry is drawing rivals in"
X Link 2025-12-09T16:44Z 5114 followers, XXX engagements

"$HIMS $LLY $NVO"
X Link 2025-12-10T19:07Z 5115 followers, XXX engagements

"$GPCR #Structure 🦉 Structure prices a $650M upsized deal selling 8.46M ADSs at $XX and adding 1.54M pre-funded warrants just below that mark. Underwriters get a 30-day option for 1.5M more as closing targets Dec. 11"
X Link 2025-12-10T19:26Z 5113 followers, XX engagements

"$NVO #Ozempic #Wegovy #China"
X Link 2025-12-10T19:48Z 5114 followers, XXX engagements

"$MRNA 🦉 Moderna president Stephen Hoge acquired XXX shares through RSU conversion and disposed of XXX shares for taxes at $XXXXX. He now holds 1454905 direct shares plus additional indirect holdings. #form_4"
X Link 2025-12-03T17:59Z 5113 followers, XXX engagements

"$REGN 🦉 Lynozyfics first-line myeloma mono posts XX% VGPR+ and XX% MRD-neg in Phase 1/2; clean safety so far ASH spotlight and a Dec XX Roundtable hints at bigger frontline ambitions"
X Link 2025-12-07T21:36Z 5113 followers, XXX engagements

"$ONC 🦉 BeOne flags standout ASH data: BRUKINSA hit XX% six-year PFS in frontline CLL and topped ibrutinib in long-term R/R follow-up. And BTK degrader BGB-16673 posted XX% ORR in heavily pretreated CLL"
X Link 2025-12-08T20:28Z 5113 followers, XXX engagements

"$PFE #GLP1 #China 🦉 Pfizer signed a licensing deal worth up to $2.1B to develop YaoPharmas early-stage GLP-1 pill. The company will pay $150M upfront. The move follows Pfizers $10B Metsera buy as it rebuilds its obesity pipeline"
X Link 2025-12-09T16:47Z 5113 followers, XXX engagements

"$HIMS $LLY $NVO"
X Link 2025-12-10T19:33Z 5113 followers, XXX engagements

"$HIMS $NVO $LLY"
X Link 2025-12-10T19:43Z 5113 followers, XXX engagements

"$HIMS $LLY $NVO"
X Link 2025-12-10T19:45Z 5113 followers, XXX engagements

"$ONC 🦉 BeOne Medicines entered a $X billion secured loan package with HSBC including $XXX million in term debt and $XXX million in revolving credit. The funds refinance offshore debt and support working capital. #form_8K"
X Link 2025-11-19T16:39Z 5113 followers, XXX engagements

"$ONC 🦉 BeOne highlights six-year BRUKINSA survival gains in CLL while early sonrotoclax data show rapid responses in tough MCL. And new BTK degrader results broaden its reach across relapsed blood cancers. #pressrelease #cancer"
X Link 2025-11-20T17:23Z 5113 followers, XXX engagements

"$ONC 🦉 This Pharma Stock Owned By Top Fund Flirts With Entry As Earnings Surge 452%. BeOne Medicines surged in 2025 as Brukinsa revenue jumped XX% to $1.04B. EPS soared XXX% while Ziihera advanced after strong Phase X data"
X Link 2025-11-21T18:20Z 5113 followers, XXX engagements

"$ABB $ETN $SIEGY $VRT"
X Link 2025-12-01T11:29Z 5113 followers, XXX engagements

"$GMAB 🦉 Genmab reports that epcoritamab helped many first-line lymphoma patients reach remission in long-term follow-up. And elderly patients on monotherapy also responded well as ASH data point to earlier-line potential"
X Link 2025-12-06T18:44Z 5113 followers, XXX engagements

"$BBIO $BBIO #JPM26"
X Link 2025-12-11T18:06Z 5113 followers, XX engagements

"$NBIS #OpenAI #AI"
X Link 2025-12-11T18:15Z 5113 followers, XXX engagements

"$NBIS $WYFI $CRWV $IREN $WULF $CIFR"
X Link 2025-12-11T18:35Z 5113 followers, XXX engagements

"$SRPT 🦉 Sarepta agreed to swap $291.4M of 2027 converts for equal 2030 notes plus $31.6M cash. The exchange lifts its 2030 note stack to $893.4M. #form_8K"
X Link 2025-12-11T18:40Z 5113 followers, XXX engagements

"$SRPT 🦉 Sarepta swaps $291.4M of its 2027 converts into new XXXXX% notes due 2030 and adds $31.6M cash to the deal. The move lifts the 2030 note stack to $893.4M while leaving $158.6M of the 2027s outstanding"
X Link 2025-12-11T18:44Z 5113 followers, XXX engagements

"$OVID 🦉 Holders approved lifting authorized shares to 315M and cleared conversion of Series B preferred and warrant exercises. Investors also approved new Series B securities for CEO Jeremy Levin. #form_8K"
X Link 2025-12-11T19:04Z 5113 followers, XXX engagements

"$NKTR $IRON $MGNX"
X Link 2025-12-06T18:01Z 5112 followers, XXX engagements

"$JNJ 🦉 J&J reports that CARVYKTI kept XX% of standard-risk myeloma patients treatment-free XXX years after a single infusion. And earlier use showed stronger immune fitness linking it to longer survival"
X Link 2025-12-06T18:46Z 5113 followers, XXX engagements

"$ONC 🦉 BRUKINSA posts a shockingly strong XX% six-year PFS in frontline CLL while BeOnes BTK degrader delivers XX% ORR at RP2D. The data tightens its grip on the CLL market"
X Link 2025-12-08T17:06Z 5112 followers, XX engagements

"$DERM 🦉 Journey Medical reports Phase X data showing Emrosis 16-week use left skin GI and vaginal microbiota unchanged. The trial met all primary endpoints with no safety issues supporting its rosacea profile"
X Link 2025-12-10T19:10Z 5113 followers, XX engagements

"$SRPT 🦉 CEO Douglas Ingram received 539084 new shares via RSU and performance-based grants at no cost. His direct holdings rose to 929391 shares after the awards. #form_4"
X Link 2025-12-10T19:51Z 5113 followers, XXX engagements